Menu
sharewise is moving On the weekend of 22/23 August the new sharewise becomes the main site. Have a look now and tell us what you miss. Go to the new sharewise What changes
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Search results

FBGRX and FDGRX Benefit From Early SpaceX ExposurePhoto, wide shot, wide-angle lens,  Cloud computing provider, Midday, harsh overhead sunlight, directional sunlightt, photo by Thomas Heaton: https://img.midjourneyapi.xyz/temp/893880f6-c6d9-4518-b1a0-f0be05207ac4.png
FBGRX and FDGRX Benefit From Early SpaceX Exposure

Fidelity Blue Chip Growth Fund FBGRX and Fidelity Growth Company Fund FDGRX, two of Fidelity’s Large Cap Growth mutual fund offerings, have delivered strong gains in 2026, helped in part by their

Performance Food Group (PFGC) Q4 Earnings and Revenues Miss EstimatesPhoto, wide shot, wide-angle lens,  Cleaning service, Midday, harsh overhead sunlight, directional sunlightt, photo by Marc Adamus: https://img.theapi.app/temp/66ee0081-ae60-418d-bd6e-b521f7433841.png
Performance Food Group (PFGC) Q4 Earnings and Revenues Miss Estimates

Performance Food Group (PFGC) came out with quarterly earnings of $1.59 per share, missing the Zacks Consensus Estimate of $1.62 per share. This compares to earnings of $1.55 per share a year ago

TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates
TScan Therapeutics, Inc. (TCRX) Reports Q2 Loss, Misses Revenue Estimates

TScan Therapeutics, Inc. (TCRX) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.29. This compares to a loss of $0.28 per share a year ago. These

Similarweb (SMWB) Tops Q2 Earnings and Revenue Estimates
Similarweb (SMWB) Tops Q2 Earnings and Revenue Estimates

Similarweb (SMWB) came out with quarterly earnings of $0.06 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.01 per share a year ago. These figures

Humacyte, Inc. (HUMA) Reports Q2 Loss, Misses Revenue Estimates
Humacyte, Inc. (HUMA) Reports Q2 Loss, Misses Revenue Estimates

Humacyte, Inc. (HUMA) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.24 per share a year ago. These figures

Trimble Navigation (TRMB) Q2 Earnings and Revenues Top Estimates
Trimble Navigation (TRMB) Q2 Earnings and Revenues Top Estimates

Trimble Navigation (TRMB) came out with quarterly earnings of $0.86 per share, beating the Zacks Consensus Estimate of $0.8 per share. This compares to earnings of $0.71 per share a year ago. These

Kontoor Brands (KTB) Beats Q2 Earnings Estimates
Kontoor Brands (KTB) Beats Q2 Earnings Estimates

Kontoor Brands (KTB) came out with quarterly earnings of $1.5 per share, beating the Zacks Consensus Estimate of $1.06 per share. This compares to earnings of $1.21 per share a year ago. These

ASP Isotopes Targets 2026 Deliveries as Helium, Radiopharmacy Expansion Gains SpeedPhoto, wide shot, wide-angle lens,  Coal mine, Midday, harsh overhead sunlight, directional sunlightt, photo by Thomas Heaton: https://img.midjourneyapi.xyz/temp/25526de2-54da-40ae-ba56-1e25dead3e81.png
ASP Isotopes Targets 2026 Deliveries as Helium, Radiopharmacy Expansion Gains Speed

Key Points

Boyd Group Services Q2 Earnings Call HighlightsPhoto, wide shot, wide-angle lens, soft focus,  Car rental company, sunset photo at golden hour, photo by Art Wolfe: https://oaidalleapiprodscus.blob.core.windows.net/private/org-IbuNdCATsFaPOITjFOv2kJh3/user-AXaxqjBUW45D8BadJEo9mUpW/img-Ew7cRec38UnlyYzs41FVEri5.png?st=2023-12-29T14%3A03%3A41Z&se=2023-12-29T16%3A03%3A41Z&sp=r&sv=2021-08-06&sr=b&rscd=inline&rsct=image/png&skoid=6aaadede-4fb3-4698-a8f6-684d7786b067&sktid=a48cca56-e6da-484e-a814-9c849652bcb3&skt=2023-12-29T15%3A03%3A25Z&ske=2023-12-30T15%3A03%3A25Z&sks=b&skv=2021-08-06&sig=vZPI3wL5I%2BC5Zknik6hYtwmYdTdsE1ct/DM1evRA8EI%3D
Boyd Group Services Q2 Earnings Call Highlights

Key Points

Annexon Q2 Earnings Call Highlights
Annexon Q2 Earnings Call Highlights

Key Points

Acumen Pharmaceuticals Q2 Earnings Call HighlightsPhoto, wide shot, wide-angle lens,  Pharmaceutical company, Midday, harsh overhead sunlight, directional sunlightt, photo by Art Wolfe: https://img.midjourneyapi.xyz/temp/7ae4a134-dd01-4c80-a621-18399f5a2541.png
Acumen Pharmaceuticals Q2 Earnings Call Highlights

Key Points

Nebius Group (NBIS) Reports Q2 Loss, Tops Revenue Estimates
Nebius Group (NBIS) Reports Q2 Loss, Tops Revenue Estimates

Nebius Group (NBIS) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.67. This compares to a loss of $0.38 per share a year ago. These figures are

Wall Street Analysts See a 26.15% Upside in TAL Education (TAL): Can the Stock Really Move This High?
Wall Street Analysts See a 26.15% Upside in TAL Education (TAL): Can the Stock Really Move This High?

TAL Education (TAL) closed the last trading session at $12.16, gaining 18.1% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall

Wall Street Analysts See a 98.74% Upside in BioCryst (BCRX): Can the Stock Really Move This High?Photo, wide shot, wide-angle lens,  Pharmaceutical company, Midday, harsh overhead sunlight, directional sunlightt, photo by Art Wolfe: https://img.midjourneyapi.xyz/temp/7ae4a134-dd01-4c80-a621-18399f5a2541.png
Wall Street Analysts See a 98.74% Upside in BioCryst (BCRX): Can the Stock Really Move This High?

Shares of BioCryst Pharmaceuticals (BCRX) have gained 6.2% over the past four weeks to close the last trading session at $10.34, but there could still be a solid upside left in the stock if

Wall Street Analysts See a 66.12% Upside in Kratos (KTOS): Can the Stock Really Move This High?
Wall Street Analysts See a 66.12% Upside in Kratos (KTOS): Can the Stock Really Move This High?

Kratos (KTOS) closed the last trading session at $63.73, gaining 26.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street

Wall Street Analysts See a 25.36% Upside in Hewlett Packard Enterprise (HPE): Can the Stock Really Move This High?
Wall Street Analysts See a 25.36% Upside in Hewlett Packard Enterprise (HPE): Can the Stock Really Move This High?

Hewlett Packard Enterprise (HPE) closed the last trading session at $54.38, gaining 9.7% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets

Can Adherex Technologies (FENC) Climb 26.53% to Reach the Level Wall Street Analysts Expect?
Can Adherex Technologies (FENC) Climb 26.53% to Reach the Level Wall Street Analysts Expect?

Shares of Adherex Technologies Inc. (FENC) have gained 14.5% over the past four weeks to close the last trading session at $12.78, but there could still be a solid upside left in the stock if

LiveOne (LVO) Reports Q1 Loss, Lags Revenue Estimates
LiveOne (LVO) Reports Q1 Loss, Lags Revenue Estimates

LiveOne (LVO) came out with a quarterly loss of $0.23 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to a loss of $0.4 per share a year ago. These figures are

Wall Street Analysts See a 28.2% Upside in BioMarin (BMRN): Can the Stock Really Move This High?Photo, wide shot, wide-angle lens,  Clinical research organization, Blue hour, twilight, cool, ISO1200, slow shutter speed, photo by Michael Light: https://img.theapi.app/temp/c28f6640-54ba-4d2b-afbe-b5fd3b0ee19e.png
Wall Street Analysts See a 28.2% Upside in BioMarin (BMRN): Can the Stock Really Move This High?

BioMarin Pharmaceutical (BMRN) closed the last trading session at $69.55, gaining 18.6% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets

Levi Strauss' DTC-First Strategy Strengthens Growth MomentumPhoto, wide shot, wide-angle lens,  Restaurant, Midday, harsh overhead sunlight, directional sunlightt, photo by Thomas Heaton: https://img.midjourneyapi.xyz/temp/6d1f34ee-79e7-4628-b30f-0a4597808d61.png
Levi Strauss' DTC-First Strategy Strengthens Growth Momentum

Levi Strauss & Co. LEVI is strengthening its direct-to-consumer (DTC) business as continued investments in retail execution, digital capabilities and customer engagement drive growth. During the